The circRNA synthesis market size was exhibited at USD 184.32 million in 2024 and is projected to hit around USD 805.44 million by 2034, growing at a CAGR of 15.89% during the forecast period 2025 to 2034.
The U.S. circRNA synthesis market size is evaluated at USD 63.59 million in 2024 and is projected to be worth around USD 277.88 million by 2034, growing at a CAGR of 14.34% from 2025 to 2034.
North America circRNA synthesis market dominated in 2024 and accounted for the market share of 46.0%. This growth can be attributed to the is driven by robust advancements in RNA-based therapeutics and the increasing prevalence of chronic diseases such as cancer and neurodegenerative disorders. Investments from biotech firms and government funding for RNA research, particularly in the U.S., are boosting innovation. The presence of key players and extensive clinical trials on circRNA therapeutics further propel circRNA synthesis industry growth in the region.
U.S. CircRNA Synthesis Market Trends
In the U.S., the market benefits from a well-established biotechnology sector and strong collaboration between academic institutions and industry players. The rising adoption of RNA-based therapies in personalized medicine and the support of FDA approvals for RNA therapies contribute significantly to the growth of circRNA synthesis technologies. Additionally, the growing demand for innovative treatments in oncology and rare diseases is a major driver.
Europe CircRNA Synthesis Market Trends
Europe's market is fueled by increased investments in biotechnology and genomic research, particularly in RNA technology. The European Union’s funding initiatives and collaborations between research institutions foster innovation in circRNA-based applications. Growing interest in advanced therapies for chronic diseases and rare genetic conditions accelerates demand for circRNA synthesis.
The UK’s circRNA synthesis market is driven by a robust biopharma ecosystem and strong government funding for RNA research. The presence of leading academic institutions focusing on RNA therapeutics and partnerships between startups and large pharmaceutical companies have significantly boosted research and commercialization efforts.
France’s focus on biopharmaceutical innovation and RNA research is driving the circRNA synthesis market. Government programs to enhance genomic research and the presence of advanced laboratories specializing in RNA-based therapies support market growth. Additionally, the country’s efforts to promote biotechnology startups provide opportunities for new developments in circRNA synthesis.
Germany’s leadership in biotechnology and pharmaceutical manufacturing is a key driver for the circRNA synthesis market. Strong funding for life sciences research, coupled with partnerships between academic institutions and biopharma companies, enhances the development of circRNA-based technologies. The growing adoption of RNA therapies in treating rare diseases and chronic conditions further boosts the circRNA synthesis industry.
Asia Pacific CircRNA Synthesis Market Trends
The Asia Pacific market for circRNA synthesis is expanding rapidly due to increased investments in biotechnology and healthcare infrastructure. Countries like China, Japan, and India are witnessing growing adoption of RNA-based therapeutics. Supportive government policies, collaborations between academic and industrial players, and rising demand for innovative treatments drive the market.
China's circRNA synthesis market is propelled by massive investments in biotechnology and a growing focus on RNA research. The government’s initiatives to promote genomics and precision medicine, combined with partnerships between domestic and international biopharma companies, are key drivers. Additionally, the increasing burden of chronic diseases creates demand for advanced RNA therapies.
In Japan, the market is driven by extensive research in RNA-based therapeutics and advancements in biopharma technology. Government funding for life sciences research and collaborations between academia and industry foster innovation. Japan’s aging population and the rising prevalence of chronic diseases further contribute to the adoption of circRNA-based treatments.
Middle East & Africa (MEA) CircRNA Synthesis Market Trends
The circRNA synthesis market in the Middle East is supported by the increasing focus on healthcare innovation and biotechnology research. Governments in the region, particularly in Saudi Arabia and the UAE, are investing heavily in genomics and advanced therapies. Rising demand for personalized medicine further boosts the adoption of circRNA synthesis technologies.
Saudi Arabia’s Vision 2030 initiative has significantly boosted investments in healthcare and biotechnology, driving the circRNA synthesis market. The establishment of advanced research facilities and partnerships with international biotech companies create opportunities for RNA-based therapies. The rising prevalence of genetic disorders and cancer fuels the demand for innovative treatments.
Kuwait’s focus on advancing healthcare infrastructure and promoting research in biotechnology supports the circRNA synthesis market. Investments in genomic research and collaborations with global biotech firms drive innovation. Additionally, the increasing burden of chronic diseases highlights the need for RNA-based therapies, further accelerating circRNA synthesis industry growth.
| Report Coverage | Details |
| Market Size in 2025 | USD 213.61 Million |
| Market Size by 2034 | USD 805.44 Million |
| Growth Rate From 2025 to 2034 | CAGR of 15.89% |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Segments Covered | Product & Services, Application, End Use, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Key Companies Profiled | LGC Biosearch Technologies; Creative Biogene;SBS Genetech; Applied Biological Materials Inc.; GenScript; Amerigo Scientific; BOC Sciences;GeneCopoeia, Inc.; Guangzhou Geneseed Biotech. Co., Ltd.; Creative Biolabs |
Reagents & kits dominated the market and accounted for a share of 47.29% in 2024. This is attributed to the Innovations in reagent formulations and kit designs, such as improved enzymatic reactions for RNA circularization and optimized buffers, are making these products more reliable and user-friendly. Additionally, the growing interest in circRNA-based therapeutics, particularly in oncology and vaccine development, is fueling demand for these tools. Companies like GenScript and New England Biolabs are actively expanding their reagent and kit offerings to cater to the rising demand, further driving growth in this circRNA synthesis industry segment.
The service segment is expected to register the highest CAGR over the forecast period. Service providers offer end-to-end solutions, including design assistance, circularization, purification, and quality control, enabling clients to accelerate their research and development timelines. The growing focus on circRNA-based drug discovery and vaccine development, particularly for applications in oncology and infectious diseases, further boosts the demand for synthesis services. Companies such as GenScript and Creative Biolabs are expanding their service portfolios to cater to the diverse and evolving needs of this burgeoning field, making tailored solutions a key market driver.
Therapeutics development accounted for the largest market revenue share of 63.81% in 2024. The development of therapeutics is a major driver for the circRNA synthesis industry, as circRNAs offer distinct advantages for medical applications, including enhanced stability, prolonged protein expression, and reduced immunogenicity compared to linear RNA. These properties make circRNAs particularly attractive for next-generation vaccines, oncology therapies, and rare genetic disease treatments. Companies like Orna Therapeutics and Circio are at the forefront of developing circRNA-based therapeutics, with ongoing efforts to address unmet clinical needs in areas such as mRNA vaccine improvements and targeted cancer therapies.
The drug discovery segment is expected to register a significant CAGR over the forecast period. The market is gaining traction in drug discovery due to the unique ability of circRNAs to modulate gene expression and protein production with high stability and efficiency. Their non-linear structure makes them resistant to exonucleases, enabling prolonged activity in cellular environments, which is crucial for high-throughput drug screening. Researchers are leveraging synthetic circRNAs to create robust in vitro models for studying disease mechanisms, testing potential drug candidates, and validating targets for therapeutic interventions, thereby driving circRNA synthesis industry growth.
Pharmaceutical and biotechnology companies accounted for the largest market revenue share of 60.0% in 2024. CircRNAs offer distinct advantages, such as enhanced stability, prolonged protein expression, and reduced immunogenicity, making them ideal for applications in next-generation RNA-based therapeutics. Leading companies are investing heavily in research and partnerships to harness the technology for novel drug development, particularly in areas like oncology, rare genetic disorders, and infectious diseases. For instance, collaborations between circRNA-focused firms like Orna Therapeutics and larger pharmaceutical companies highlight the growing recognition of circRNAs' therapeutic value. Furthermore, the success of mRNA vaccines has shifted industry focus toward RNA technologies, positioning circRNAs as a transformative tool for pipeline diversification and addressing unmet clinical needs.
The academic and research institutes segment is expected to register a significant CAGR during the forecast period. The versatility of circRNAs in gene regulation, protein production, and therapeutic applications has fueled academic interest, resulting in an increase in research grants and funding for RNA-based projects. Institutes are actively exploring circRNA's roles in cancer, neurological disorders, and rare diseases, as well as their applications in developing vaccines and gene therapies. Furthermore, advancements in custom synthesis services and reagents have made circRNA research more accessible, enabling institutions to delve into novel therapeutic pathways. Collaborative efforts between academia and biotechnology companies are also accelerating translational research, driving innovation and fostering the adoption of circRNA technologies in early-stage drug discovery and development. This is expected to help this segment grow positively in this market.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the circRNA synthesis market
By Product & Services
By Application
By End Use
By Regional
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers